

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6007601

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MIRX THERAPEUTICS APS	02/12/2020
RECEIVING PARTY DATA	
Name:	GUANGDONG MAIJINJIA BIOTECHNOLOGY CO., LTD
Street Address:	11TH FLOOR, NO.247 SCIENCE AVENUE, HUANGPU DISTRICT,
City:	GUANGZHOU,
State/Country:	CHINA
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8691965
CORRESPONDENCE DATA	
Fax Number:	(703)739-2815
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	iprecordals@cpaglobal.com
Correspondent Name:	CPA GLOBAL LIMITED
Address Line 1:	LIBERATION HOUSE
Address Line 2:	CASTLE STREET
Address Line 4:	ST HELIER, JERSEY JE1 IBL
NAME OF SUBMITTER:	HEIDI WHITTINGHAM
SIGNATURE:	/IPR/FV/BuddeScho2020_012MirTherap/AG1P/
DATE SIGNED:	03/11/2020
Total Attachments: 2 source=Deed#page1.tif source=Deed#page2.tif	

UNITED STATES OF AMERICA
ASSIGNMENT

WHEREAS Mirx Therapeutics ApS ("ASSIGNOR") a Limited company organized under the laws of Denmark with a place of business at c/o Liplasome Pharma A/S Diplomvej 378 DK-2800 Kongens Lyngby Denmark owns the United States Patent(s) (the "Patent(s)") listed on the attached Schedule A; and

WHEREAS Guangdong Maijinjia Biotechnology Co. Ltd ("ASSIGNEE") a Limited company organized under the laws of China with a place of business at 11th Floor No.247 Science Avenue Huangpu District Guangzhou China desires to acquire all rights to the Patent(s);

NOW THEREFORE in consideration of One Dollar (\$1.00) and other valuable consideration the receipt of which ASSIGNOR acknowledges ASSIGNOR has sold assigned transferred and set over and does by this Assignment sell assign transfer and set over unto ASSIGNEE all rights to the Patent(s) including reissues and extensions to be held and enjoyed by ASSIGNEE its successors assigns and legal representatives for ASSIGNEE's own use and benefit and for the use and benefit of its successors assigns and legal representatives to the end of the term(s) for which the Patent(s) have been granted or may be reissued or extended as fully and entirely as the Patent(s) would have been held and enjoyed by ASSIGNOR had this assignment and sale not been made; together with all claims for profits and damages by reason of past infringement with the right to sue for and collect the same for the use and benefit of ASSIGNEE its successors assigns and legal representatives.

This Assignment is deemed to have become effective as from: 12.02.2020.....

IN WITNESS WHEREOF ASSIGNOR and ASSIGNEE have caused this Assignment to be executed by its duly authorized officer or representative on the date(s) indicated below.

By: Mirx Therapeutics ApS

Name: Thorbjørn Møller

Title: CEO

Date: 12.02.2020

By: Guangdong Maijinjia Biotechnology Co. Ltd

Name: Jianjie Zhai

Title: Chief Executive Officer

Date: 12/02/2020

Schedule

Country	Application Number	IP Grant Number
U.S.A.	12664502	8691965